Search Results

PathMaker Neurosystems Inc. announced that it has received a funding award of $2.16 million from the Congressionally Directed Medical Research Program at the United States Department of Defense’s U.S. Army Medical Research and Development Command, as part of its FY23 Amyotrophic Lateral Sclerosis Research Program Pilot Clinical Trial Award.

PathMaker Neurosystems Inc. announced the initiation of a first-in-human clinical trial evaluating its MyoRegulator® device for the treatment of amyotrophic lateral sclerosis.

PathMaker Neurosystems Inc. was selected as one of five companies in Massachusetts to receive a START Stage 2 award from MassVentures, which funds deep tech startups based in Massachusetts as they advance technology developed under SBIR/STTR grant funding.

The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. announced today an investment of $600,000 through the MDA Venture Philanthropy (MVP) program to PathMaker to advance its work in amyotrophic lateral sclerosis (ALS).

PathMaker Neurosystems Inc., a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, was selected as a recipient of a START award from MassVentures, which funds deep tech startups based in Massachusetts as they advance technology developed under NIH SBIR/STTR funding.

PathMaker Neurosystems Inc. announced that it was awarded a CERF Medical Electronics Prize from the Cullen Education and Research Fund, a private philanthropy based in London, United Kingdom.

PathMaker Neurosystems Inc. announced initiation of its U.S. multi-center clinical trial to evaluate MyoRegulator® for the non-invasive treatment of post-stroke upper-limb spasticity.

PathMaker Neurosystems Inc. has named William C. Mills, to the Company’s Board of Directors.